The Biotech category semifinalist pitches are now live on the EIT Health Catapult platform on-demand. Register here for free to see all the pitches. The finalists will be announced later in the Spring, and the top companies will present live at the Bits and Pretzels Healthtech event in Munich in June.

The global Junior Chamber International organization selects StemSight CEO Laura among this year's Ten Outstanding Young Persons of the World. Amazing news!

StemSight has been selected as the winner from Finland in the Silicon Vikings New Nordics pitching competition. The Nordic and Baltic finalists will compete against each other in the Grand Finals during Slush Week in November.

StemSight has been selected among the 14 European Biotech startups selected to compete in the semifinals of EIT Health's Catapult programme. Each year, the competition showcases Europe’s most promising biotech, medtech and digital health start-ups to leading experts and investors. 

StemSight was selected among the best presenting companies in two consecutive events organized by Tech Tour. The European Healthtech Investment Forum and the Future22 flagship event for the very best innovative companies.

StemSight received the 50 000 € Silmu grant from Instrumentarium Science Foundation. The foundation has a long history in supporting research in medical technologies and life science.

Business Finland, Spinverse and Technology Industry Finland have selected our CTO and founder, Prof. Heli Skottman as one of the three finalists for the 2nd Innovation Professor of the Year award. We're very proud of her!

Our CEO, Dr. Laura Koivusalo has been selected as one of the Outstanding Young Persons of the Year by Junior Chamber International Finland. Laura was selected from the category of Medical Innovation, and the selection committee highlighted her merits in academic research, startup entrepreneurship as well as her volunteer work.

Following the press release of StemSight's seed investment, the prime European startup media Sifted did a great piece on the future of stem cell therapies to cure blindness, by interviewing our CEO Laura.

We are proud to announce the successful seed funding round lead by Finnish deep-tech VC Voima Ventures and Avohoidon tutkimussäätiö. This funding goes to further development of StemSight's cell therapy product for limbal stem cell defiency.

​The Finnish Centre for Economic Development has granted 190 k€ in funding for advancement of StemSight's limbal stem cell deficiency product development. The funding is part of EU's regional development funding.